CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer...
Phase 2
London, United Kingdom and 29 other locations
The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a s...
Phase 2
London, United Kingdom and 31 other locations
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
London, United Kingdom and 262 other locations
A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop dise...
Phase 3
London, United Kingdom and 12 other locations
to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...
Phase 1, Phase 2
London, United Kingdom and 85 other locations
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with re...
Phase 1
Cambridge, Cambridgeshire, United Kingdom and 26 other locations
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablatio...
Phase 1, Phase 2
London, United Kingdom and 15 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET...
Phase 1, Phase 2
London, Greater London, United Kingdom and 25 other locations
chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer....
Phase 3
London, United Kingdom and 282 other locations
To assess:* efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification...
Phase 2
London, United Kingdom and 41 other locations
Clinical trials
Research sites
Resources
Legal